Ashish Srinivasan

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 23

Top Venues

Alimentary pharmacology & therapeutics

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Journal of gastroenterology and hepatology

The Medical journal of Australia

Oxford University Hospitals NHS Foundation Trust

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Oxford University Hospitals NHS Foundation Trust

United Kingdom

Senior Clinical Fellow :: Department of Gastroenterology

Publications

Ashish Srinivasan, Daniel van Langenberg, Peter De Cruz, Jonathan Segal, Abhinav Vasudevan, Richard N Upton
Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (5) (2024)
Bridgette Andrew, Steven Trinh, Annie Zhou, Abhinav Vasudevan, Ashish Srinivasan
Anal Cancer in Crohn's Disease: The Need to Optimize Treatment and Improve Surveillance. The American journal of gastroenterology 119 (2) (2024)
Ashish Srinivasan, Daniel van Langenberg, Peter De Cruz, Jonathan Segal, Abhinav Vasudevan, Richard N Upton
Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2024)
Ashish Srinivasan, Daniel van Langenberg, Peter De Cruz, Jonathan Segal, Abhinav Vasudevan, Richard N Upton
Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (5) (2024)
Bridgette Andrew, Steven Trinh, Annie Zhou, Abhinav Vasudevan, Ashish Srinivasan
Anal Cancer in Crohn's Disease: The Need to Optimize Treatment and Improve Surveillance. The American journal of gastroenterology 119 (2) (2024)
Ashish Srinivasan, Daniel van Langenberg, Peter De Cruz, Jonathan Segal, Abhinav Vasudevan, Richard N Upton
Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (5) (2024)
Patrick Hilley, Danny Con, Matthew C Choy, Ashish Srinivasan, Peter De Cruz
Upadacitinib in end stage renal disease: A case of acute severe ulcerative colitis. JGH open : an open access journal of gastroenterology and hepatology 7 (12) (2023)
Bridgette Andrew, Annie Zhou, Steven Trinh, Ashish Srinivasan, Abhinav Vasudevan
Letter: Antibiotics in gut dysbiosis and development of inflammatory bowel disease-More thought is needed. Alimentary pharmacology & therapeutics 58 (8) (2023)
Ashish Srinivasan, Peter De Cruz, Melissa Sam, Catherine Toong, Daniel R Van Langenberg
Dose intensification strategy influences infliximab pharmacokinetics but not clinical response after the same number of doses. Journal of gastroenterology and hepatology (2023)
Patrick Hilley, Danny Con, Matthew C Choy, Ashish Srinivasan, Peter De Cruz
Upadacitinib in end stage renal disease: A case of acute severe ulcerative colitis. JGH open : an open access journal of gastroenterology and hepatology 7 (12) (2023)
Bridgette Andrew, Ashish Srinivasan, Annie Zhou, Abhinav Vasudevan
Letter: Elderly onset inflammatory bowel disease-Treat to target approach is still warranted. Alimentary pharmacology & therapeutics 58 (5) (2023)
Ashish Srinivasan, Peter De Cruz, Melissa Sam, Catherine Toong, Daniel R Van Langenberg
Dose intensification strategy influences infliximab pharmacokinetics but not clinical response after the same number of doses. Journal of gastroenterology and hepatology (2023)
Ashish Srinivasan, Robert Gilmore, Daniel van Langenberg, Peter De Cruz
Systematic review and meta-analysis: evaluating response to empiric anti-TNF dose intensification for secondary loss of response in Crohn's disease. Therapeutic advances in gastroenterology 15 (2022)
Ashish Srinivasan, Craig Haifer, Lena Thin
Editorial: outcomes following a second switch-evaluating clinical outcomes and patient perspectives in IBD. Alimentary pharmacology & therapeutics 53 (9) (2021)
Robert Gilmore, Patrick Hilley, Ashish Srinivasan, Matthew Choy, Peter De Cruz
Sequential use of high-dose tofacitinib after infliximab salvage therapy in acute severe ulcerative colitis. Journal of Crohn's & colitis (2021)
Ashish Srinivasan, Daniel R Van Langenberg
Editorial: does anti-TNF "treatment persistence" always equate to "effective treatment"? Only objective disease assessments can answer the question. Alimentary pharmacology & therapeutics 54 (5) (2021)
Ashish Srinivasan, Craig Haifer, Lena Thin
Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab. The Medical journal of Australia 215 (9) (2021)
Ashish Srinivasan, Daniel van Langenberg, Peter De Cruz
Real-World Effectiveness of Ustekinumab Dose Intensification in Crohn's Disease. Inflammatory bowel diseases 27 (6) (2021)
Craig Haifer, Ashish Srinivasan, Yoon-Kyo An, Sherman Picardo, Daniel van Langenberg, Shankar Menon, Jakob Begun, Simon Ghaly, Lena Thin
Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study. The Medical journal of Australia 214 (3) (2020)
Ashish Srinivasan, Peter De Cruz, Daniel R Van Langenberg
Letter: ustekinumab dose intensification for loss of response-should we re-induce before shortening the dose interval? Alimentary pharmacology & therapeutics 52 (3) (2020)
Ashish Srinivasan, Peter De Cruz, Daniel R Van Langenberg
Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail. Alimentary pharmacology & therapeutics 52 (3) (2020)
Ashish Srinivasan, Peter De Cruz, Daniel R van Langenberg
Anti-TNF-associated immunogenicity: use a retroactive drug but a proactive approach. Gut 70 (4) (2020)
Ashish Srinivasan, Daniel R Van Langenberg, Robert D Little, Miles P Sparrow, Peter De Cruz, Mark G Ward
A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn's disease. Alimentary pharmacology & therapeutics 51 (12) (2020)

Ashish Srinivasan.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Ashish Srinivasan